by Mark Harrington 19 September 1998 Late every August, the once-and-future greats (and some not-so greats) of AIDS research pay pilgrimage to HIV co-discoverer Robert C. Gallo at the annual laboratory meeting once, in palmier days, hosted in Bethesda by…
A Critical Review of New Antiretroviral Drugs & Treatment Strategies June 1998 By Spencer Cox, Jill Cadman, Paul Dietz, Mark Harrington, Winston Layne, Luis Santiago & Theo Smart Introduction by Spencer Cox In January, 1996, at the Third Conference on…
AIDS Related Opportunistic Infections Report (Version 2.0) By Michael Marco, Steve Kass, Paul Dietz, Laura Morrison, Theo Smart, Evan Wilder, Tim Horn and Mark Harrington February 1998 From the Introduction Six years ago, at the Amsterdam AIDS Conference, I joined…
Maximal HIV Suppression becomes the Goal of Antiretroviral Therapy Unequal Access to Care Still Hinders Treatment Advances Members of the Treatment Action Group (TAG), a non-profit AIDS research and treatment advocacy group in New York City, offered strong praise for…
Scientific and Regulatory Issues in the Era of Antiretrovirai Polytherapy and a Viral Load-Driven Standard of Care (Version 0.5) A Report to the FDA Antiviral Drugs Advisory Committee 14 July 1997 by Spencer Cox, Paul Dietz, Mark Harrington & Theo…
ACTG 320 Proves that Indinavir and 3TC, when Added to AZT, Reduce AIDS and Death by Half when Compared with AZT and 3TC without Indinavir in HIV-Positive Individuals with Fewer than 200 CD4 Cells and Over Three Months of AZT…
A Report from the 11th International Conference on AIDS Vancouver, British Columbia, 8-11 July 1996 By Mark Harrington From the Introduction The year 1996 has brought a sea change in AIDS research and treatment. Three major factors have contributed to…
From 1996 by Mark Harrington After Berlin, no one could credibly believe that AIDS drug development was on track. Indeed, it looked likely that the various initiatives AIDS activists had worked with FDA, NIH and industry to develop were actually…